Stage IIIB Skin Melanoma Completed Phase 2 Trials for Sirolimus (DB00877)

IndicationStatusPhase
DBCOND0029534 (Stage IIIB Skin Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00397982Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant MelanomaTreatment